 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ( Checkpoint ) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ( Checkpoint ) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT  Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest...

Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Expands By 6.1%

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT  Free Report)  Analysts at B. Riley issued their Q3 2023 EPS estimates for shares of Checkpoint Therapeutics in a report released on Monday, August 21st. B. Riley analyst M. Mamtani expects that the company will earn ($0.89) per share for the ...

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Expected to Earn Q3 2023 Earnings of ($0.89) Per Share

Checkpoint Therapeutics (NASDAQ:CKPT  Free Report) had its price objective reduced by LADENBURG THALM/SH SH from $65.00 to $47.00 in a research report sent to investors on Tuesday , MarketBeat Ratings reports. They currently have a buy rating on the stock. Other equities analysts have also ...

Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Lowered to $47.00 at LADENBURG THALM/SH SH

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT  Free Report)  Stock analysts at Cantor Fitzgerald raised their FY2023 earnings estimates for shares of Checkpoint Therapeutics in a...

Brokers Offer Predictions for Checkpoint Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT  Free Report) had its target price trimmed by Cantor Fitzgerald from $19.00 to $14.00 in a research report report published on Tuesday , Marketbeat reports. The brokerage currently has an overweight rating on the stock. Cantor Fitzgerald also issued ...

Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Lowered to $14.00 at Cantor Fitzgerald

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT Free Report) Equities research analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Checkpoint Therapeutics in a research report issued on Tuesday, August 15th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings ...

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Expected to Earn FY2024 Earnings of $0.66 Per Share

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Checkpoint Therapeutics price target lowered to $47 from $65 at Ladenburg

Checkpoint Therapeutics price target lowered to $14 from $19 at Cantor Fitzgerald

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Watchers	4,923
52-Wk Low	$1.30
52-Wk High	$11.50

Market Cap	$30.02M
Volume (M)	126,274.00
52-Wk High	$11.50
52-Wk Low	$1.30

CKPT Checkpoint Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals